IRIS PubliCatt

Voso, Maria Teresa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.818
NA - Nord America 4.318
AS - Asia 1.708
SA - Sud America 34
AF - Africa 32
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 4
Totale 10.928
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.301
DE - Germania 1.933
CN - Cina 1.037
SE - Svezia 746
PL - Polonia 567
UA - Ucraina 457
SG - Singapore 328
IT - Italia 306
FR - Francia 197
IE - Irlanda 183
GB - Regno Unito 150
IN - India 112
FI - Finlandia 110
ID - Indonesia 104
RU - Federazione Russa 73
TR - Turchia 50
JP - Giappone 23
CI - Costa d'Avorio 22
BR - Brasile 20
BE - Belgio 19
NL - Olanda 16
CA - Canada 14
AU - Australia 12
VN - Vietnam 11
IR - Iran 9
KR - Corea 9
CZ - Repubblica Ceca 8
ES - Italia 7
CH - Svizzera 6
CO - Colombia 6
TH - Thailandia 6
ZA - Sudafrica 6
BG - Bulgaria 5
GR - Grecia 5
AE - Emirati Arabi Uniti 4
HK - Hong Kong 4
LT - Lituania 4
NO - Norvegia 4
RO - Romania 4
AT - Austria 3
MX - Messico 3
PK - Pakistan 3
SK - Slovacchia (Repubblica Slovacca) 3
EC - Ecuador 2
EU - Europa 2
HR - Croazia 2
IL - Israele 2
LV - Lettonia 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
BO - Bolivia 1
CL - Cile 1
DK - Danimarca 1
EG - Egitto 1
GH - Ghana 1
HU - Ungheria 1
IS - Islanda 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MA - Marocco 1
ME - Montenegro 1
MK - Macedonia 1
MY - Malesia 1
PE - Perù 1
PY - Paraguay 1
SA - Arabia Saudita 1
TN - Tunisia 1
UY - Uruguay 1
Totale 10.928
Salva come PNG Salva come JPEG
Città #
Chandler 762
Warsaw 561
Jacksonville 341
Ashburn 305
Singapore 242
Nanjing 224
San Mateo 214
Dearborn 193
Ann Arbor 182
Houston 181
Dublin 174
Woodbridge 166
Wilmington 164
Hangzhou 158
Nürnberg 125
Fairfield 119
Beijing 116
Jakarta 103
Seattle 92
New York 87
Milan 80
Nanchang 80
Lawrence 75
Bremen 74
Munich 64
Cattolica 63
Redwood City 56
Boston 54
Kunming 53
Moscow 53
Los Angeles 51
Cambridge 42
Izmir 42
Shenyang 35
Lancaster 34
Marseille 32
Shanghai 32
University Park 31
Auburn Hills 29
Leawood 29
Hefei 27
Tianjin 26
Chicago 25
Hebei 25
Jiaxing 25
Princeton 25
Changsha 24
Fremont 24
Zhengzhou 23
Abidjan 22
Falls Church 21
Mountain View 21
Norwalk 20
Rome 19
Helsinki 18
Brussels 17
Chatsworth 16
Guangzhou 16
Jinan 15
Lanzhou 14
Pune 14
Augusta 13
Boardman 13
Detroit 12
London 12
Philadelphia 10
Simi Valley 10
San Diego 9
São Paulo 9
Edinburgh 8
Frankfurt am Main 8
Monmouth Junction 8
Redmond 8
Changchun 7
Costa Mesa 7
Hanoi 7
Ningbo 7
San Jose 7
Washington 7
Alghero 6
Busto Arsizio 6
Ypsilanti 6
Berlin 5
Chengdu 5
Kraków 5
New Delhi 5
Ottawa 5
Sacramento 5
Santa Clara 5
Tokyo 5
Amsterdam 4
Gurgaon 4
Hong Kong 4
Indiana 4
Medellín 4
Mumbai 4
Seo-gu 4
Seoul 4
Sydney 4
Taizhou 4
Totale 6.215
Salva come PNG Salva come JPEG
Nome #
Incidence of acute myeloid leukemia after breast cancer 336
Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome 305
Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia 266
Fanconi anemia gene variants in therapy-related myeloid neoplasms 259
THE PROGNOSTIC ROLE OF EBV IN PERIPHERAL BLOOD OF PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA 231
Therapy-related leukemias and myelodysplasia : susceptibility and incidence. 221
Quantification of DAPK1 Promoter Methylation in Bone Marrow and Peripheral Blood as a Follicular Lymphoma Biomarker 211
Mutational analysis of bone marrow mesenchymal stromal cells in myeloid malignancies 206
Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. 184
PTEN/PI3K/AKT PATHWAY DYSREGULATION IN MYELODYSPLASTIC GRANULOCYTES 175
MUTATIONAL ANALYSIS OF BONE MARROW MESENCHIMAL STROMAL CELLS IN MYELOID MALIGNANCIES 169
Anemia in Diffuse Large B cell Non-Hodgkin Lymphoma: The Role of IL-6, Hepcidin and Erythropoietin 166
Defective WNT Signaling and Genetic Profile Of Endothelial Cells In Patients With Low Risk Myelodysplastic Syndromes Suggest a Contribution Of Vascular Niches To Myelodysplasia 161
GSK3β down-regulation in Mesenchymal Stem Cells from patients with Myelodysplastic Syndrome. 157
Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin 155
CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma 154
DEREGULATION OF PI3K/AKT SIGNALING IN BONE MARROW MESENCHIMAL STROMAL CELLS FROM PATIENTS WITH DE NOVO AND THERAPY-RELATED ACUTE MYELOID LEUKEMIA 140
MTHFR polymorphysms in myelodysplastic syndromes and therapy-related myeloid neoplasms 139
Why methylation is not a marker predictive of response to hypomethylating agents 137
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma 136
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the italian network on secondary leukemias. 135
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 134
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. 133
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 133
SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms. 133
Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome 130
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma 127
Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome 125
Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia 124
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database 124
Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. 122
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. 121
Gemtuzumab ozogamicin, citosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia. 119
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. 118
Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine 116
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 115
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma 113
Primary plasma cell leukemia followed by testicular plasmacytoma 113
Iron in Hodgkin's lymphoma 110
Epigenetic changes in therapy-related MDS/AML 107
Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto SCTsuccessfully treated with combination treatment. 107
Similarities and differences between therapy-related and elderly acute myeloid leukemia 107
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 107
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes 104
Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma 104
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 103
5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature 103
Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma. 102
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas 101
Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma 101
PU.1 and CEBPA expression in acute myeloid leukemia. 98
Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia. 96
Outcome of therapy-related myeloid neoplasms treated with azacitidine 95
DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma 94
DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma. 93
The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes 91
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. 90
Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine. 90
Clonal evolution in therapy-related neoplasms 90
Small lymphocytic lymphoma in a patient with Fabry disease 86
Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma. 85
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma 82
Endothelial progenitor cell dysfunction in myelodysplastic syndromes: possible contribution of a defective vascular niche to myelodysplasia 82
Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma 80
Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study 80
Efficacy of combined surgery and antifungal therapies for the management of invasive zygomycoses in patients with haematological malignancies 79
Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine 79
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 79
An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome 78
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule 77
The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression. 76
Negative prognostic value of glutathione s-transferase (gstm1 and gstt1) deletions in adult acute myeloid leukemia. 76
Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome 76
Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. 73
High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study 72
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 72
Deferasirox for Transfusion-Dependent Patients with Myelodysplastic Syndromes: Safety, Efficacy, and Beyond (GIMEMA MDS0306 Trial) 70
Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy 70
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma) 69
Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma 69
Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma 69
Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia 66
Therapy-related myeloid neoplasms 64
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation 62
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation 61
Therapy-related myeloid neoplasms: Clinical perspectives 60
Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial 59
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine 58
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a “Gruppo Romano Mielodisplasie (GROM)” multicenter study 58
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 57
A population-based study on myelodysplastic syndromes in the Lazio Region (Italy), medical miscoding and 11-year mortality follow-up: The Gruppo Romano-Laziale Mielodisplasie experience of retrospective multicentric registry 56
Efficacy and toxicicty of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer 55
Chronic myelomonocytic leukemia treatment with azacitidine: What have we learned so far? 54
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis 53
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ) 53
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes 51
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes 44
Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders 41
Telomerase activity in human hematopoietic progenitor cells 37
Real-Life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile 35
Totale 10.939
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.428
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.428
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.250 0 0 0 0 207 268 152 69 169 122 128 135
2020/20211.334 63 120 21 108 152 132 203 27 135 79 260 34
2021/2022969 119 105 7 31 77 39 24 170 47 87 127 136
2022/20232.059 260 291 159 375 122 256 75 186 243 7 61 24
2023/2024861 40 270 15 20 33 156 34 34 13 24 114 108
2024/2025516 47 62 158 62 187 0 0 0 0 0 0 0
Totale 11.001